Avanos Medical Stock Price, News & Analysis

Avanos Medical (NYSE: AVNS) has scheduled a conference call to discuss its first quarter 2025 financial results on Tuesday, May 6 at 9 a.m. ET. The company will release its detailed results before the market opens on the same day.

The conference call will feature key leadership including CEO Dave Pacitti, interim CFO Jason Pickett, SVP of Strategy and Corporate Development Scott Galovan, and Board Chairman Gary Blackford. Participants can join via phone through an automatic registration system or through manual dialing options.

A simultaneous webcast and presentation will be available through the Investors section of Avanos Medical's website. The replay will be accessible for one week following the call.

Avanos Medical (NYSE: AVNS) announced it will take direct control of sales and distribution for its MIC-KEY enteral feeding products in the United Kingdom starting July 25, 2025. This change ends a 29-year distribution partnership with Vygon UK, who has been distributing the MIC* and MIC-KEY product family.

The strategic transition aims to strengthen Avanos' direct relationship with healthcare professionals and patients, while ensuring product availability and customer support. MIC-KEY, a low-profile feeding tube system for enteral nutrition, is currently distributed in over 60 countries across six continents and has been trusted by clinicians and patients for over 25 years.

Avanos will provide guidance to healthcare providers currently purchasing through Vygon UK to ensure a smooth transition with minimal disruption to the ordering process.

Avanos Medical (NYSE: AVNS) has appointed David Pacitti as its new Chief Executive Officer, effective April 14, 2025. Pacitti joins from Siemens Medical Solutions USA, where he served as president and Head of the Americas for Siemens Healthineers, overseeing marketing, sales, service, and support functions across North and Latin America.

Pacitti brings extensive healthcare industry experience, including leadership roles at Abbott Vascular, where he served as division vice president of U.S. commercial operations and played key roles in launching the company's first drug-eluting stent franchise. His prior experience includes positions at Guidant Corp from 1995 to 2006.

Currently, Pacitti serves as chair of AdvaMed Medical Imaging Technology Division's board and holds board positions at Orchestra BioMed and the Siemens Foundation. He holds a bachelor's degree from Villanova University and an MBA from the University of Maryland.

Avanos Medical (NYSE: AVNS) reported its Q4 and full-year 2024 results, showing mixed performance. Q4 net sales reached $179.6 million, up 3.6% year-over-year, while full-year sales grew 2.2% to $687.8 million.

The company recorded a significant Q4 net loss of $397.0 million, largely due to a $436.7 million impairment charge on goodwill and intangible assets. Despite this, free cash flow improved to $82.9 million for 2024, compared to $14.6 million in 2023.

Q4 adjusted earnings per share increased to $0.43 from $0.36 year-over-year, while full-year adjusted EPS rose to $1.35 from $1.03. The company's net debt decreased to $27.0 million from $80.3 million previous year.

For 2025, Avanos projects net sales between $665-685 million and adjusted EPS of $1.05-1.25, reflecting challenging market conditions and currency headwinds.

Avanos Medical (NYSE: AVNS) has scheduled a conference call and webcast for Wednesday, Feb. 26 at 9 a.m. ET to discuss its fourth quarter and full year 2024 financial results. The company will release detailed financial results before the market opens on the same day. Michael Greiner, interim CEO, and Scott Galovan, senior vice president of strategy and corporate development, will host the call.

Participants can join the conference call through an automatic registration link or by dialing directly. A simultaneous webcast and related presentation will be available through the Investors section of the Avanos Medical website. The replay will be accessible for one week after the call.

Avanos Medical is a medical technology company based in Alpharetta, Georgia, focusing on medical device solutions for patient care, particularly in nutrition delivery and post-surgical recovery with reduced opioid use.

Avanos Medical (NYSE: AVNS) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. Michael Greiner, the company's interim chief executive officer, will deliver a presentation on Monday, January 13, at approximately 3:45 p.m. PST.

The presentation will be accessible via webcast through the Investors section of the Avanos Medical website, where it will also be archived for future reference.

Avanos Medical (NYSE: AVNS) has announced its participation in the Stifel 2024 Healthcare Conference. Michael Greiner, interim CEO, will engage in an analyst-led fireside chat at the Lotte New York Palace on Tuesday, Nov. 19 at 3:35 p.m. ET. The presentation will be accessible via webcast on the company's website's Investors section, where it will also be archived for future reference.

The Centers for Medicare and Medicaid Services (CMS) announced that Avanos Medical's ON-Q elastomeric infusion pump and ambIT disposable electronic infusion pump will receive separate Medicare payments under the NOPAIN Act starting January 1, 2025. This decision, part of the Medicare Hospital Outpatient Prospective Payment System (OPPS) and Medicare Ambulatory Surgical Center (ASC) Payment System rule for 2025, aims to enhance access to non-opioid pain management in HOPD and ASC settings. The NOPAIN Act, effective until December 31, 2027, provides additional Medicare reimbursement for qualifying non-opioid items to reduce opioid reliance. Both ON-Q and ambIT pumps will have unique HCPCS codes (C9804 and C9806) and a payment limit of up to $2,284.98 each. This move by CMS is a significant step in promoting safer pain management alternatives for Medicare beneficiaries.